CA3193070A1 - Autoinjector with shock reducing elements - Google Patents
Autoinjector with shock reducing elementsInfo
- Publication number
- CA3193070A1 CA3193070A1 CA3193070A CA3193070A CA3193070A1 CA 3193070 A1 CA3193070 A1 CA 3193070A1 CA 3193070 A CA3193070 A CA 3193070A CA 3193070 A CA3193070 A CA 3193070A CA 3193070 A1 CA3193070 A1 CA 3193070A1
- Authority
- CA
- Canada
- Prior art keywords
- piston
- injection device
- plunger
- constriction
- members
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000035939 shock Effects 0.000 title description 7
- 229940090047 auto-injector Drugs 0.000 title description 5
- 238000002347 injection Methods 0.000 claims abstract description 190
- 239000007924 injection Substances 0.000 claims abstract description 190
- 230000007246 mechanism Effects 0.000 claims abstract description 158
- 239000003814 drug Substances 0.000 claims abstract description 112
- 238000013016 damping Methods 0.000 claims abstract description 105
- 229940079593 drug Drugs 0.000 claims abstract description 99
- 238000000034 method Methods 0.000 claims abstract description 75
- 239000011358 absorbing material Substances 0.000 claims abstract description 27
- 238000012377 drug delivery Methods 0.000 claims abstract description 15
- 239000000463 material Substances 0.000 claims description 49
- 239000012530 fluid Substances 0.000 claims description 46
- 230000002093 peripheral effect Effects 0.000 claims description 40
- 230000002829 reductive effect Effects 0.000 claims description 22
- 230000033001 locomotion Effects 0.000 claims description 12
- 230000002691 anti-thymic effect Effects 0.000 claims description 9
- 239000003173 antianemic agent Substances 0.000 claims description 8
- 229940125367 erythropoiesis stimulating agent Drugs 0.000 claims description 8
- 102000005741 Metalloproteases Human genes 0.000 claims description 6
- 108010006035 Metalloproteases Proteins 0.000 claims description 6
- 102000007644 Colony-Stimulating Factors Human genes 0.000 claims description 5
- 108010071942 Colony-Stimulating Factors Proteins 0.000 claims description 5
- 229940047120 colony stimulating factors Drugs 0.000 claims description 5
- 239000003112 inhibitor Substances 0.000 claims description 5
- 108091008803 APLNR Proteins 0.000 claims description 4
- 102000016555 Apelin receptors Human genes 0.000 claims description 4
- 102000014468 Calcitonin Gene-Related Peptide Receptors Human genes 0.000 claims description 4
- 108010078311 Calcitonin Gene-Related Peptide Receptors Proteins 0.000 claims description 4
- 230000003213 activating effect Effects 0.000 claims description 4
- 239000000018 receptor agonist Substances 0.000 claims description 4
- 229940044601 receptor agonist Drugs 0.000 claims description 4
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 claims description 4
- 239000002451 tumor necrosis factor inhibitor Substances 0.000 claims description 4
- 101710172072 Kexin Proteins 0.000 claims 2
- 108010044159 Proprotein Convertases Proteins 0.000 claims 2
- 102000006437 Proprotein Convertases Human genes 0.000 claims 2
- 108090000787 Subtilisin Proteins 0.000 claims 2
- 229950000128 lumiliximab Drugs 0.000 description 49
- 102000004169 proteins and genes Human genes 0.000 description 49
- 108090000623 proteins and genes Proteins 0.000 description 49
- 102000005962 receptors Human genes 0.000 description 17
- 108020003175 receptors Proteins 0.000 description 17
- 239000010410 layer Substances 0.000 description 12
- 108010074604 Epoetin Alfa Proteins 0.000 description 10
- 102100034980 ICOS ligand Human genes 0.000 description 8
- 229960003388 epoetin alfa Drugs 0.000 description 8
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 7
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 7
- 239000000825 pharmaceutical preparation Substances 0.000 description 7
- 230000010437 erythropoiesis Effects 0.000 description 6
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 6
- 102000003951 Erythropoietin Human genes 0.000 description 5
- 108090000394 Erythropoietin Proteins 0.000 description 5
- 108010075944 Erythropoietin Receptors Proteins 0.000 description 5
- 102100036509 Erythropoietin receptor Human genes 0.000 description 5
- 102100021866 Hepatocyte growth factor Human genes 0.000 description 5
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 description 5
- 229960004579 epoetin beta Drugs 0.000 description 5
- 229940105423 erythropoietin Drugs 0.000 description 5
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 5
- 229960001972 panitumumab Drugs 0.000 description 5
- -1 polyethylene Polymers 0.000 description 5
- 230000004936 stimulating effect Effects 0.000 description 5
- 108010029961 Filgrastim Proteins 0.000 description 4
- 101001019455 Homo sapiens ICOS ligand Proteins 0.000 description 4
- 102000002265 Human Growth Hormone Human genes 0.000 description 4
- 108010000521 Human Growth Hormone Proteins 0.000 description 4
- 239000000854 Human Growth Hormone Substances 0.000 description 4
- 101710093458 ICOS ligand Proteins 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 102000014128 RANK Ligand Human genes 0.000 description 4
- 108010025832 RANK Ligand Proteins 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 229940126534 drug product Drugs 0.000 description 4
- 108010002601 epoetin beta Proteins 0.000 description 4
- 108010067416 epoetin delta Proteins 0.000 description 4
- 229950002109 epoetin delta Drugs 0.000 description 4
- 108010081679 epoetin theta Proteins 0.000 description 4
- 229950008826 epoetin theta Drugs 0.000 description 4
- 108010030868 epoetin zeta Proteins 0.000 description 4
- 229950005185 epoetin zeta Drugs 0.000 description 4
- 108010044644 pegfilgrastim Proteins 0.000 description 4
- 239000004033 plastic Substances 0.000 description 4
- 229920003023 plastic Polymers 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- ZJNLYGOUHDJHMG-UHFFFAOYSA-N 1-n,4-n-bis(5-methylhexan-2-yl)benzene-1,4-diamine Chemical compound CC(C)CCC(C)NC1=CC=C(NC(C)CCC(C)C)C=C1 ZJNLYGOUHDJHMG-UHFFFAOYSA-N 0.000 description 3
- 102000004414 Calcitonin Gene-Related Peptide Human genes 0.000 description 3
- 108010019673 Darbepoetin alfa Proteins 0.000 description 3
- 108010008165 Etanercept Proteins 0.000 description 3
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 3
- 102100039939 Growth/differentiation factor 8 Human genes 0.000 description 3
- 101001098868 Homo sapiens Proprotein convertase subtilisin/kexin type 9 Proteins 0.000 description 3
- 102000038455 IGF Type 1 Receptor Human genes 0.000 description 3
- 108010031794 IGF Type 1 Receptor Proteins 0.000 description 3
- 102100026261 Metalloproteinase inhibitor 3 Human genes 0.000 description 3
- 108090000445 Parathyroid hormone Proteins 0.000 description 3
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 3
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 3
- 102100034196 Thrombopoietin receptor Human genes 0.000 description 3
- 108010031429 Tissue Inhibitor of Metalloproteinase-3 Proteins 0.000 description 3
- 102100036922 Tumor necrosis factor ligand superfamily member 13B Human genes 0.000 description 3
- 239000003570 air Substances 0.000 description 3
- 230000027455 binding Effects 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 229960004177 filgrastim Drugs 0.000 description 3
- 102000044389 human CD22 Human genes 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 229940127557 pharmaceutical product Drugs 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 239000012858 resilient material Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 2
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 2
- 102100034608 Angiopoietin-2 Human genes 0.000 description 2
- 102100038080 B-cell receptor CD22 Human genes 0.000 description 2
- 101800000407 Brain natriuretic peptide 32 Proteins 0.000 description 2
- 108090000932 Calcitonin Gene-Related Peptide Proteins 0.000 description 2
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 2
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 2
- 101000924533 Homo sapiens Angiopoietin-2 Proteins 0.000 description 2
- 101000610604 Homo sapiens Tumor necrosis factor receptor superfamily member 10B Proteins 0.000 description 2
- 102000019223 Interleukin-1 receptor Human genes 0.000 description 2
- 108050006617 Interleukin-1 receptor Proteins 0.000 description 2
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 description 2
- 108700021006 Interleukin-1 receptor antagonist Proteins 0.000 description 2
- 102000010787 Interleukin-4 Receptors Human genes 0.000 description 2
- 108010038486 Interleukin-4 Receptors Proteins 0.000 description 2
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 2
- 108010056852 Myostatin Proteins 0.000 description 2
- 102100036893 Parathyroid hormone Human genes 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 108700002718 TACI receptor-IgG Fc fragment fusion Proteins 0.000 description 2
- 101710148535 Thrombopoietin receptor Proteins 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- 102100040112 Tumor necrosis factor receptor superfamily member 10B Human genes 0.000 description 2
- 108010023082 activin A Proteins 0.000 description 2
- 239000004964 aerogel Substances 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 102000023732 binding proteins Human genes 0.000 description 2
- 108091008324 binding proteins Proteins 0.000 description 2
- 229950007296 cantuzumab mertansine Drugs 0.000 description 2
- 229960003115 certolizumab pegol Drugs 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 229960002806 daclizumab Drugs 0.000 description 2
- 229960005029 darbepoetin alfa Drugs 0.000 description 2
- 229960001251 denosumab Drugs 0.000 description 2
- 239000013536 elastomeric material Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229950009760 epratuzumab Drugs 0.000 description 2
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 2
- 229960000403 etanercept Drugs 0.000 description 2
- OLNTVTPDXPETLC-XPWALMASSA-N ezetimibe Chemical compound N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 OLNTVTPDXPETLC-XPWALMASSA-N 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 229960001743 golimumab Drugs 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 229960005386 ipilimumab Drugs 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- KHPKQFYUPIUARC-UHFFFAOYSA-N lumiracoxib Chemical compound OC(=O)CC1=CC(C)=CC=C1NC1=C(F)C=CC=C1Cl KHPKQFYUPIUARC-UHFFFAOYSA-N 0.000 description 2
- 229960000994 lumiracoxib Drugs 0.000 description 2
- 229950001869 mapatumumab Drugs 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229940071846 neulasta Drugs 0.000 description 2
- 229960003301 nivolumab Drugs 0.000 description 2
- 230000000174 oncolytic effect Effects 0.000 description 2
- 108010046821 oprelvekin Proteins 0.000 description 2
- HQQSBEDKMRHYME-UHFFFAOYSA-N pefloxacin mesylate Chemical compound [H+].CS([O-])(=O)=O.C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCN(C)CC1 HQQSBEDKMRHYME-UHFFFAOYSA-N 0.000 description 2
- 229960001373 pegfilgrastim Drugs 0.000 description 2
- 229960002087 pertuzumab Drugs 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 229940071643 prefilled syringe Drugs 0.000 description 2
- 229960004641 rituximab Drugs 0.000 description 2
- 108010017584 romiplostim Proteins 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 229960004532 somatropin Drugs 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 229950008461 talimogene laherparepvec Drugs 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- 229920001169 thermoplastic Polymers 0.000 description 2
- 239000004416 thermosoftening plastic Substances 0.000 description 2
- 239000003190 viscoelastic substance Substances 0.000 description 2
- 229950001212 volociximab Drugs 0.000 description 2
- 229950008250 zalutumumab Drugs 0.000 description 2
- HMLGSIZOMSVISS-ONJSNURVSA-N (7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2,2-dimethylpropanoyloxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@@H]1C(N2C(=C(C=C)CSC21)C(O)=O)=O)C(=O)\C(=N/OCOC(=O)C(C)(C)C)C1=CSC(N)=N1 HMLGSIZOMSVISS-ONJSNURVSA-N 0.000 description 1
- UHTZABZWCSJMDY-UHFFFAOYSA-N 2-(chloromethyl)oxirane;n,n,n',n'-tetrakis(3-aminopropyl)butane-1,4-diamine Chemical compound ClCC1CO1.NCCCN(CCCN)CCCCN(CCCN)CCCN UHTZABZWCSJMDY-UHFFFAOYSA-N 0.000 description 1
- PFWVGKROPKKEDW-UHFFFAOYSA-N 2-[4-[4-(tert-butylcarbamoyl)-2-[(2-chloro-4-cyclopropylphenyl)sulfonylamino]phenoxy]-5-chloro-2-fluorophenyl]acetic acid Chemical compound C=1C=C(C2CC2)C=C(Cl)C=1S(=O)(=O)NC1=CC(C(=O)NC(C)(C)C)=CC=C1OC1=CC(F)=C(CC(O)=O)C=C1Cl PFWVGKROPKKEDW-UHFFFAOYSA-N 0.000 description 1
- RTQWWZBSTRGEAV-PKHIMPSTSA-N 2-[[(2s)-2-[bis(carboxymethyl)amino]-3-[4-(methylcarbamoylamino)phenyl]propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical compound CNC(=O)NC1=CC=C(C[C@@H](CN(CC(C)N(CC(O)=O)CC(O)=O)CC(O)=O)N(CC(O)=O)CC(O)=O)C=C1 RTQWWZBSTRGEAV-PKHIMPSTSA-N 0.000 description 1
- MZZYGYNZAOVRTG-UHFFFAOYSA-N 2-hydroxy-n-(1h-1,2,4-triazol-5-yl)benzamide Chemical compound OC1=CC=CC=C1C(=O)NC1=NC=NN1 MZZYGYNZAOVRTG-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- MJZJYWCQPMNPRM-UHFFFAOYSA-N 6,6-dimethyl-1-[3-(2,4,5-trichlorophenoxy)propoxy]-1,6-dihydro-1,3,5-triazine-2,4-diamine Chemical compound CC1(C)N=C(N)N=C(N)N1OCCCOC1=CC(Cl)=C(Cl)C=C1Cl MJZJYWCQPMNPRM-UHFFFAOYSA-N 0.000 description 1
- ZKRFOXLVOKTUTA-KQYNXXCUSA-N 9-(5-phosphoribofuranosyl)-6-mercaptopurine Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(NC=NC2=S)=C2N=C1 ZKRFOXLVOKTUTA-KQYNXXCUSA-N 0.000 description 1
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 1
- 102000018746 Apelin Human genes 0.000 description 1
- 108010052412 Apelin Proteins 0.000 description 1
- 102100030949 Apelin receptor Human genes 0.000 description 1
- 101100067974 Arabidopsis thaliana POP2 gene Proteins 0.000 description 1
- 108010028006 B-Cell Activating Factor Proteins 0.000 description 1
- 229960005509 CAT-3888 Drugs 0.000 description 1
- 229940124296 CD52 monoclonal antibody Drugs 0.000 description 1
- 229940045513 CTLA4 antagonist Drugs 0.000 description 1
- 101100381481 Caenorhabditis elegans baz-2 gene Proteins 0.000 description 1
- 101100179591 Caenorhabditis elegans ins-22 gene Proteins 0.000 description 1
- 102000009410 Chemokine receptor Human genes 0.000 description 1
- 108050000299 Chemokine receptor Proteins 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 1
- 102100038497 Cytokine receptor-like factor 2 Human genes 0.000 description 1
- 101710194733 Cytokine receptor-like factor 2 Proteins 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 102000001301 EGF receptor Human genes 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 108091006020 Fc-tagged proteins Proteins 0.000 description 1
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 description 1
- 102400000322 Glucagon-like peptide 1 Human genes 0.000 description 1
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 1
- 101150043052 Hamp gene Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 1
- 101000741445 Homo sapiens Calcitonin Proteins 0.000 description 1
- 101100118549 Homo sapiens EGFR gene Proteins 0.000 description 1
- 101000599940 Homo sapiens Interferon gamma Proteins 0.000 description 1
- 101001010568 Homo sapiens Interleukin-11 Proteins 0.000 description 1
- 101000669513 Homo sapiens Metalloproteinase inhibitor 1 Proteins 0.000 description 1
- 101000845170 Homo sapiens Thymic stromal lymphopoietin Proteins 0.000 description 1
- 101000830603 Homo sapiens Tumor necrosis factor ligand superfamily member 11 Proteins 0.000 description 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 1
- 102000016844 Immunoglobulin-like domains Human genes 0.000 description 1
- 108050006430 Immunoglobulin-like domains Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- 108010078049 Interferon alpha-2 Proteins 0.000 description 1
- 108010005716 Interferon beta-1a Proteins 0.000 description 1
- 102000003996 Interferon-beta Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102100030694 Interleukin-11 Human genes 0.000 description 1
- 102000013264 Interleukin-23 Human genes 0.000 description 1
- 108010065637 Interleukin-23 Proteins 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 description 1
- 102000048850 Neoplasm Genes Human genes 0.000 description 1
- 108700019961 Neoplasm Genes Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 102000003982 Parathyroid hormone Human genes 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 101710180553 Proprotein convertase subtilisin/kexin type 9 Proteins 0.000 description 1
- 102100038955 Proprotein convertase subtilisin/kexin type 9 Human genes 0.000 description 1
- 101710194807 Protective antigen Proteins 0.000 description 1
- 101100372762 Rattus norvegicus Flt1 gene Proteins 0.000 description 1
- 101100123851 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) HER1 gene Proteins 0.000 description 1
- 101100289055 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) LIH1 gene Proteins 0.000 description 1
- 101710084578 Short neurotoxin 1 Proteins 0.000 description 1
- 206010041925 Staphylococcal infections Diseases 0.000 description 1
- 108010039185 Tenecteplase Proteins 0.000 description 1
- 108010070774 Thrombopoietin Receptors Proteins 0.000 description 1
- 102100031294 Thymic stromal lymphopoietin Human genes 0.000 description 1
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 1
- 108050006955 Tissue-type plasminogen activator Proteins 0.000 description 1
- 101710182223 Toxin B Proteins 0.000 description 1
- 101710182532 Toxin a Proteins 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 108091008605 VEGF receptors Proteins 0.000 description 1
- 108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 description 1
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 1
- 229960000446 abciximab Drugs 0.000 description 1
- 229940119059 actemra Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 229960002964 adalimumab Drugs 0.000 description 1
- 229950009084 adecatumumab Drugs 0.000 description 1
- 229960000548 alemtuzumab Drugs 0.000 description 1
- 229960003318 alteplase Drugs 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 229960004238 anakinra Drugs 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- BWVPHIKGXQBZPV-QKFDDRBGSA-N apelin Chemical compound NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N1[C@H](C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=2NC=NC=2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=2NC=NC=2)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CCSC)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(O)=O)CCC1 BWVPHIKGXQBZPV-QKFDDRBGSA-N 0.000 description 1
- 229940115115 aranesp Drugs 0.000 description 1
- 229950009925 atacicept Drugs 0.000 description 1
- 229940120638 avastin Drugs 0.000 description 1
- 229940003504 avonex Drugs 0.000 description 1
- 229960004669 basiliximab Drugs 0.000 description 1
- 229960003270 belimumab Drugs 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 229950007940 bixalomer Drugs 0.000 description 1
- 229950005042 blosozumab Drugs 0.000 description 1
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 1
- 229960001467 bortezomib Drugs 0.000 description 1
- 229960003735 brodalumab Drugs 0.000 description 1
- 108700001003 carbamylated erythropoietin Proteins 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940090100 cimzia Drugs 0.000 description 1
- VDHAWDNDOKGFTD-MRXNPFEDSA-N cinacalcet Chemical compound N([C@H](C)C=1C2=CC=CC=C2C=CC=1)CCCC1=CC=CC(C(F)(F)F)=C1 VDHAWDNDOKGFTD-MRXNPFEDSA-N 0.000 description 1
- 229960003315 cinacalcet Drugs 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229950007276 conatumumab Drugs 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 108010084052 continuous erythropoietin receptor activator Proteins 0.000 description 1
- 230000003413 degradative effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- FWZTTZUKDVJDCM-CEJAUHOTSA-M disodium;(2r,3r,4s,5s,6r)-2-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol;iron(3+);oxygen(2-);hydroxide;trihydrate Chemical compound O.O.O.[OH-].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[Na+].[Na+].[Fe+3].[Fe+3].[Fe+3].[Fe+3].[Fe+3].O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 FWZTTZUKDVJDCM-CEJAUHOTSA-M 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 229960002224 eculizumab Drugs 0.000 description 1
- 229960001776 edrecolomab Drugs 0.000 description 1
- 229960000284 efalizumab Drugs 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 229940073621 enbrel Drugs 0.000 description 1
- 108010090921 epoetin omega Proteins 0.000 description 1
- 229950008767 epoetin omega Drugs 0.000 description 1
- 229940089118 epogen Drugs 0.000 description 1
- 229940082789 erbitux Drugs 0.000 description 1
- 229960001433 erlotinib Drugs 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 229940102709 ferumoxytol Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 229950001109 galiximab Drugs 0.000 description 1
- 229950004896 ganitumab Drugs 0.000 description 1
- 229960003297 gemtuzumab ozogamicin Drugs 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 108010013846 hematide Proteins 0.000 description 1
- 102000049885 human IL11 Human genes 0.000 description 1
- 102000053529 human TNFSF11 Human genes 0.000 description 1
- 229940045644 human calcitonin Drugs 0.000 description 1
- 229940048921 humira Drugs 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- UCNNJGDEJXIUCC-UHFFFAOYSA-L hydroxy(oxo)iron;iron Chemical compound [Fe].O[Fe]=O.O[Fe]=O UCNNJGDEJXIUCC-UHFFFAOYSA-L 0.000 description 1
- 229960001001 ibritumomab tiuxetan Drugs 0.000 description 1
- 230000003116 impacting effect Effects 0.000 description 1
- 229960000598 infliximab Drugs 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229960003521 interferon alfa-2a Drugs 0.000 description 1
- 108010010648 interferon alfacon-1 Proteins 0.000 description 1
- 229960003358 interferon alfacon-1 Drugs 0.000 description 1
- 229960001388 interferon-beta Drugs 0.000 description 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 description 1
- 229940032961 iron sucrose Drugs 0.000 description 1
- 229940054136 kineret Drugs 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 229950010470 lerdelimumab Drugs 0.000 description 1
- 229940087875 leukine Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 208000015688 methicillin-resistant staphylococcus aureus infectious disease Diseases 0.000 description 1
- 229960001046 methoxy polyethylene glycol-epoetin beta Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 229950000720 moxetumomab pasudotox Drugs 0.000 description 1
- 229960003816 muromonab-cd3 Drugs 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- ONDPWWDPQDCQNJ-UHFFFAOYSA-N n-(3,3-dimethyl-1,2-dihydroindol-6-yl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide;phosphoric acid Chemical compound OP(O)(O)=O.OP(O)(O)=O.C=1C=C2C(C)(C)CNC2=CC=1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 ONDPWWDPQDCQNJ-UHFFFAOYSA-N 0.000 description 1
- 229960005027 natalizumab Drugs 0.000 description 1
- 229920003052 natural elastomer Polymers 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 229920001194 natural rubber Polymers 0.000 description 1
- 229960001267 nesiritide Drugs 0.000 description 1
- HPNRHPKXQZSDFX-OAQDCNSJSA-N nesiritide Chemical compound C([C@H]1C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1N=CNC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 HPNRHPKXQZSDFX-OAQDCNSJSA-N 0.000 description 1
- 229940082926 neumega Drugs 0.000 description 1
- 229940029345 neupogen Drugs 0.000 description 1
- 229950010203 nimotuzumab Drugs 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 229950005751 ocrelizumab Drugs 0.000 description 1
- 229960002450 ofatumumab Drugs 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 229950008516 olaratumab Drugs 0.000 description 1
- 229960000470 omalizumab Drugs 0.000 description 1
- 229960001840 oprelvekin Drugs 0.000 description 1
- 229950007283 oregovomab Drugs 0.000 description 1
- 229940029358 orthoclone okt3 Drugs 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 229960000402 palivizumab Drugs 0.000 description 1
- 239000000199 parathyroid hormone Substances 0.000 description 1
- 229960001319 parathyroid hormone Drugs 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 108010048732 pegylated erythropoietin Proteins 0.000 description 1
- 229950003203 pexelizumab Drugs 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229940092597 prolia Drugs 0.000 description 1
- 229960003876 ranibizumab Drugs 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 229940116176 remicade Drugs 0.000 description 1
- 229940107685 reopro Drugs 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229950003238 rilotumumab Drugs 0.000 description 1
- 229960004262 romiplostim Drugs 0.000 description 1
- 229950010968 romosozumab Drugs 0.000 description 1
- 108010038379 sargramostim Proteins 0.000 description 1
- WUWDLXZGHZSWQZ-WQLSENKSSA-N semaxanib Chemical compound N1C(C)=CC(C)=C1\C=C/1C2=CC=CC=C2NC\1=O WUWDLXZGHZSWQZ-WQLSENKSSA-N 0.000 description 1
- 229940115586 simulect Drugs 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229940036185 synagis Drugs 0.000 description 1
- 229920003051 synthetic elastomer Polymers 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 229940120982 tarceva Drugs 0.000 description 1
- 229960000216 tenecteplase Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960005267 tositumomab Drugs 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- 108010075758 trebananib Proteins 0.000 description 1
- 229950001210 trebananib Drugs 0.000 description 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
- 229940079023 tysabri Drugs 0.000 description 1
- 229960003824 ustekinumab Drugs 0.000 description 1
- 229950009578 vidupiprant Drugs 0.000 description 1
- 229950004393 visilizumab Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 229940014556 xgeva Drugs 0.000 description 1
- 229950009002 zanolimumab Drugs 0.000 description 1
- 229940051223 zetia Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/3129—Syringe barrels
- A61M5/3134—Syringe barrels characterised by constructional features of the distal end, i.e. end closest to the tip of the needle cannula
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
- A61M5/2033—Spring-loaded one-shot injectors with or without automatic needle insertion
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
- A61M5/31511—Piston or piston-rod constructions, e.g. connection of piston with piston-rod
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/32—Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
- A61M5/3205—Apparatus for removing or disposing of used needles or syringes, e.g. containers; Means for protection against accidental injuries from used needles
- A61M5/321—Means for protection against accidental injuries by used needles
- A61M5/3243—Means for protection against accidental injuries by used needles being axially-extensible, e.g. protective sleeves coaxially slidable on the syringe barrel
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F16—ENGINEERING ELEMENTS AND UNITS; GENERAL MEASURES FOR PRODUCING AND MAINTAINING EFFECTIVE FUNCTIONING OF MACHINES OR INSTALLATIONS; THERMAL INSULATION IN GENERAL
- F16F—SPRINGS; SHOCK-ABSORBERS; MEANS FOR DAMPING VIBRATION
- F16F9/00—Springs, vibration-dampers, shock-absorbers, or similarly-constructed movement-dampers using a fluid or the equivalent as damping medium
- F16F9/06—Springs, vibration-dampers, shock-absorbers, or similarly-constructed movement-dampers using a fluid or the equivalent as damping medium using both gas and liquid
- F16F9/08—Springs, vibration-dampers, shock-absorbers, or similarly-constructed movement-dampers using a fluid or the equivalent as damping medium using both gas and liquid where gas is in a chamber with a flexible wall
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F16—ENGINEERING ELEMENTS AND UNITS; GENERAL MEASURES FOR PRODUCING AND MAINTAINING EFFECTIVE FUNCTIONING OF MACHINES OR INSTALLATIONS; THERMAL INSULATION IN GENERAL
- F16F—SPRINGS; SHOCK-ABSORBERS; MEANS FOR DAMPING VIBRATION
- F16F9/00—Springs, vibration-dampers, shock-absorbers, or similarly-constructed movement-dampers using a fluid or the equivalent as damping medium
- F16F9/10—Springs, vibration-dampers, shock-absorbers, or similarly-constructed movement-dampers using a fluid or the equivalent as damping medium using liquid only; using a fluid of which the nature is immaterial
- F16F9/103—Devices with one or more members moving linearly to and fro in chambers, any throttling effect being immaterial, i.e. damping by viscous shear effect only
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F16—ENGINEERING ELEMENTS AND UNITS; GENERAL MEASURES FOR PRODUCING AND MAINTAINING EFFECTIVE FUNCTIONING OF MACHINES OR INSTALLATIONS; THERMAL INSULATION IN GENERAL
- F16F—SPRINGS; SHOCK-ABSORBERS; MEANS FOR DAMPING VIBRATION
- F16F9/00—Springs, vibration-dampers, shock-absorbers, or similarly-constructed movement-dampers using a fluid or the equivalent as damping medium
- F16F9/10—Springs, vibration-dampers, shock-absorbers, or similarly-constructed movement-dampers using a fluid or the equivalent as damping medium using liquid only; using a fluid of which the nature is immaterial
- F16F9/14—Devices with one or more members, e.g. pistons, vanes, moving to and fro in chambers and using throttling effect
- F16F9/16—Devices with one or more members, e.g. pistons, vanes, moving to and fro in chambers and using throttling effect involving only straight-line movement of the effective parts
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F16—ENGINEERING ELEMENTS AND UNITS; GENERAL MEASURES FOR PRODUCING AND MAINTAINING EFFECTIVE FUNCTIONING OF MACHINES OR INSTALLATIONS; THERMAL INSULATION IN GENERAL
- F16F—SPRINGS; SHOCK-ABSORBERS; MEANS FOR DAMPING VIBRATION
- F16F9/00—Springs, vibration-dampers, shock-absorbers, or similarly-constructed movement-dampers using a fluid or the equivalent as damping medium
- F16F9/10—Springs, vibration-dampers, shock-absorbers, or similarly-constructed movement-dampers using a fluid or the equivalent as damping medium using liquid only; using a fluid of which the nature is immaterial
- F16F9/14—Devices with one or more members, e.g. pistons, vanes, moving to and fro in chambers and using throttling effect
- F16F9/16—Devices with one or more members, e.g. pistons, vanes, moving to and fro in chambers and using throttling effect involving only straight-line movement of the effective parts
- F16F9/18—Devices with one or more members, e.g. pistons, vanes, moving to and fro in chambers and using throttling effect involving only straight-line movement of the effective parts with a closed cylinder and a piston separating two or more working spaces therein
- F16F9/20—Devices with one or more members, e.g. pistons, vanes, moving to and fro in chambers and using throttling effect involving only straight-line movement of the effective parts with a closed cylinder and a piston separating two or more working spaces therein with the piston-rod extending through both ends of the cylinder, e.g. constant-volume dampers
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F16—ENGINEERING ELEMENTS AND UNITS; GENERAL MEASURES FOR PRODUCING AND MAINTAINING EFFECTIVE FUNCTIONING OF MACHINES OR INSTALLATIONS; THERMAL INSULATION IN GENERAL
- F16F—SPRINGS; SHOCK-ABSORBERS; MEANS FOR DAMPING VIBRATION
- F16F9/00—Springs, vibration-dampers, shock-absorbers, or similarly-constructed movement-dampers using a fluid or the equivalent as damping medium
- F16F9/32—Details
- F16F9/3207—Constructional features
- F16F9/3228—Constructional features of connections between pistons and piston rods
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F16—ENGINEERING ELEMENTS AND UNITS; GENERAL MEASURES FOR PRODUCING AND MAINTAINING EFFECTIVE FUNCTIONING OF MACHINES OR INSTALLATIONS; THERMAL INSULATION IN GENERAL
- F16F—SPRINGS; SHOCK-ABSORBERS; MEANS FOR DAMPING VIBRATION
- F16F9/00—Springs, vibration-dampers, shock-absorbers, or similarly-constructed movement-dampers using a fluid or the equivalent as damping medium
- F16F9/32—Details
- F16F9/34—Special valve constructions; Shape or construction of throttling passages
- F16F9/348—Throttling passages in the form of annular discs or other plate-like elements which may or may not have a spring action, operating in opposite directions or singly, e.g. annular discs positioned on top of the valve or piston body
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F16—ENGINEERING ELEMENTS AND UNITS; GENERAL MEASURES FOR PRODUCING AND MAINTAINING EFFECTIVE FUNCTIONING OF MACHINES OR INSTALLATIONS; THERMAL INSULATION IN GENERAL
- F16F—SPRINGS; SHOCK-ABSORBERS; MEANS FOR DAMPING VIBRATION
- F16F9/00—Springs, vibration-dampers, shock-absorbers, or similarly-constructed movement-dampers using a fluid or the equivalent as damping medium
- F16F9/32—Details
- F16F9/34—Special valve constructions; Shape or construction of throttling passages
- F16F9/348—Throttling passages in the form of annular discs or other plate-like elements which may or may not have a spring action, operating in opposite directions or singly, e.g. annular discs positioned on top of the valve or piston body
- F16F9/3481—Throttling passages in the form of annular discs or other plate-like elements which may or may not have a spring action, operating in opposite directions or singly, e.g. annular discs positioned on top of the valve or piston body characterised by shape or construction of throttling passages in piston
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F16—ENGINEERING ELEMENTS AND UNITS; GENERAL MEASURES FOR PRODUCING AND MAINTAINING EFFECTIVE FUNCTIONING OF MACHINES OR INSTALLATIONS; THERMAL INSULATION IN GENERAL
- F16F—SPRINGS; SHOCK-ABSORBERS; MEANS FOR DAMPING VIBRATION
- F16F9/00—Springs, vibration-dampers, shock-absorbers, or similarly-constructed movement-dampers using a fluid or the equivalent as damping medium
- F16F9/32—Details
- F16F9/36—Special sealings, including sealings or guides for piston-rods
- F16F9/361—Sealings of the bellows-type
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
- A61M2005/2086—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically having piston damping means, e.g. axially or rotationally acting retarders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M2005/3143—Damping means for syringe components executing relative movements, e.g. retarders or attenuators slowing down or timing syringe mechanisms
Landscapes
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Mechanical Engineering (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Vascular Medicine (AREA)
- Anesthesiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Environmental & Geological Engineering (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461990063P | 2014-05-07 | 2014-05-07 | |
| US61/990,063 | 2014-05-07 | ||
| CA2945026A CA2945026C (en) | 2014-05-07 | 2015-05-06 | Autoinjector with shock reducing elements |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2945026A Division CA2945026C (en) | 2014-05-07 | 2015-05-06 | Autoinjector with shock reducing elements |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3193070A1 true CA3193070A1 (en) | 2015-11-12 |
Family
ID=53200314
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3193070A Pending CA3193070A1 (en) | 2014-05-07 | 2015-05-06 | Autoinjector with shock reducing elements |
| CA2945026A Active CA2945026C (en) | 2014-05-07 | 2015-05-06 | Autoinjector with shock reducing elements |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2945026A Active CA2945026C (en) | 2014-05-07 | 2015-05-06 | Autoinjector with shock reducing elements |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US10722655B2 (enExample) |
| EP (2) | EP3785749A1 (enExample) |
| JP (3) | JP6640113B2 (enExample) |
| KR (1) | KR102496507B1 (enExample) |
| CN (1) | CN106413779B (enExample) |
| AU (1) | AU2015256082C1 (enExample) |
| BR (1) | BR112016025852B1 (enExample) |
| CA (2) | CA3193070A1 (enExample) |
| IL (1) | IL247935B (enExample) |
| MX (1) | MX388536B (enExample) |
| SG (2) | SG10201811702TA (enExample) |
| WO (1) | WO2015171777A1 (enExample) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016163642A (ja) * | 2015-03-06 | 2016-09-08 | 大成化工株式会社 | 針付きバレル及びこれを備えたシリンジ |
| FR3036966B1 (fr) * | 2015-06-05 | 2021-10-01 | Aptar France Sas | Autoinjecteur |
| WO2017089289A1 (en) * | 2015-11-27 | 2017-06-01 | Sanofi-Aventis Deutschland Gmbh | Auto-injector |
| JOP20170042B1 (ar) | 2016-02-12 | 2022-09-15 | Amgen Inc | وسيلة توصيل عقار، طريقة تصنيعه وطريقة استخدامه |
| EP3429663B1 (en) * | 2016-03-15 | 2020-07-15 | Amgen Inc. | Reducing probability of glass breakage in drug delivery devices |
| EP3439715B1 (en) | 2016-04-08 | 2021-03-10 | Amgen Inc. | Drug delivery device |
| US10549044B2 (en) | 2016-06-09 | 2020-02-04 | Becton, Dickinson And Company | Spacer assembly for drug delivery system |
| US20180015224A1 (en) * | 2016-07-13 | 2018-01-18 | California Institute Of Technology | Dampers and Methods for Performing Measurements in an Autoinjector |
| GB2553770A (en) * | 2016-09-09 | 2018-03-21 | Owen Mumford Ltd | Injection device |
| JP7051839B2 (ja) * | 2016-11-01 | 2022-04-11 | サノフィ－アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 注射デバイス用のフィードバック機構 |
| EP3348294A1 (en) * | 2017-01-13 | 2018-07-18 | Carebay Europe Ltd. | Medicament delivery device |
| MX2019008432A (es) * | 2017-01-17 | 2019-11-18 | Amgen Inc | Dispositivos de inyeccion y metodos relacionados de uso y ensamblaje. |
| WO2018236619A1 (en) * | 2017-06-22 | 2018-12-27 | Amgen Inc. | Device activation impact/shock reduction |
| CN112312948B (zh) * | 2018-04-19 | 2022-12-02 | 赛诺菲 | 用于注射装置的缓冲器 |
| CN112292167B (zh) * | 2018-04-19 | 2023-01-20 | 赛诺菲 | 注射装置中的力减小 |
| EP3860685A1 (en) * | 2018-10-02 | 2021-08-11 | Amgen Inc. | Injection systems for drug delivery with internal force transmission |
| MA53912A (fr) | 2018-10-15 | 2022-01-19 | Amgen Inc | Dispositif d'administration de médicament comprenant un mécanisme d'amortissement |
| AU2019370159B2 (en) | 2018-11-01 | 2025-05-29 | Amgen Inc. | Drug delivery devices with partial drug delivery member retraction |
| TWI831847B (zh) * | 2018-11-01 | 2024-02-11 | 美商安進公司 | 部分針頭縮回之藥物遞送裝置及其操作方法 |
| EP3873566B1 (en) | 2018-11-01 | 2024-11-27 | Amgen Inc. | Drug delivery devices with partial drug delivery member retraction |
| KR20220088701A (ko) | 2019-09-25 | 2022-06-28 | 얀센 파마슈티칼즈, 인코포레이티드 | 약물 투여 시스템의 상호 연결 |
| WO2021067209A1 (en) * | 2019-09-30 | 2021-04-08 | Amgen Inc. | Drug delivery device |
| JP7075977B2 (ja) * | 2020-10-09 | 2022-05-26 | 成田空港給油施設株式会社 | シリンジ |
| JP2024508715A (ja) | 2021-02-12 | 2024-02-28 | アルタヴィズ，リミティッド・ライアビリティ・カンパニー | 外部動力式シリンジドライバおよびこれを使用するシステムおよび方法 |
| US11311666B1 (en) | 2021-02-18 | 2022-04-26 | Fresenius Kabi Deutschland Gmbh | Modular wearable medicament delivery device and method of use thereof |
| US11872369B1 (en) | 2021-02-18 | 2024-01-16 | Fresenius Kabi Deutschland Gmbh | Wearable medicament delivery device with leakage and skin contact sensing and method of use thereof |
| US11464902B1 (en) | 2021-02-18 | 2022-10-11 | Fresenius Kabi Deutschland Gmbh | Wearable medicament delivery device with compressible reservoir and method of use thereof |
| US11406755B1 (en) | 2021-02-19 | 2022-08-09 | Fresenius Kabi Deutschland Gmbh | Sensing fluid flow irregularities in an on-body injector |
| US11497847B1 (en) | 2021-02-19 | 2022-11-15 | Fresenius Kabi Deutschland Gmbh | Wearable injector with adhesive substrate |
| US11607505B1 (en) | 2021-02-19 | 2023-03-21 | Fresenius Kabi Deutschland Gmbh | Wearable injector with sterility sensors |
| US11344682B1 (en) | 2021-02-19 | 2022-05-31 | Fresenius Kabi Deutschland Gmbh | Drug supply cartridge with visual use indicator and delivery devices that use the same |
| US11426523B1 (en) | 2021-02-19 | 2022-08-30 | Fresenius Kabi Deutschland Gmbh | Drug delivery assembly including a removable cartridge |
| US11633537B1 (en) | 2021-02-19 | 2023-04-25 | Fresenius Kabi Deutschland Gmbh | Drug delivery assembly including a pre-filled cartridge |
| US11413394B1 (en) | 2021-02-19 | 2022-08-16 | Fresenius Kabi Deutschland Gmbh | Display for wearable drug delivery device |
| JPWO2022191136A1 (enExample) * | 2021-03-12 | 2022-09-15 | ||
| EP4313213A1 (en) * | 2021-03-25 | 2024-02-07 | Amgen Inc. | Drug delivery device |
| US11529459B1 (en) | 2021-04-30 | 2022-12-20 | Fresenius Kabi Deutschland Gmbh | Wearable injector with adhesive module |
| US11351300B1 (en) | 2021-04-30 | 2022-06-07 | Fresenius Kabl Deutschland GmbH | Drug dispensing system with replaceable drug supply cartridges |
| US11504470B1 (en) | 2021-04-30 | 2022-11-22 | Fresenius Kabi Deutschland Gmbh | Deformable drug reservoir for wearable drug delivery device |
| US11419976B1 (en) | 2021-04-30 | 2022-08-23 | Fresenius Kabi Deutschland Gmbh | Wearable drug delivery device with pressurized fluid dispensing |
| US11717608B1 (en) | 2021-05-03 | 2023-08-08 | Fresenius Kabi Deutschland Gmbh | Drug delivery assembly including an adhesive pad |
| US11484646B1 (en) | 2021-05-04 | 2022-11-01 | Fresenius Kabi Deutschland Gmbh | Sealing systems for a reservoir of an on-body injector |
| JP2023165377A (ja) * | 2022-05-02 | 2023-11-15 | コスメディ製薬株式会社 | マイクロニードル用アプリケータ |
| US12110324B2 (en) | 2022-07-22 | 2024-10-08 | Flagship Pioneering Innovations Vi, Llc | Antigen binding molecules targeting thymic stromal lymphopoietin (TSLP) |
| US12420017B1 (en) * | 2025-02-26 | 2025-09-23 | Genzyme Corporation | Damping device for a medicament delivery device |
Family Cites Families (222)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE537349A (enExample) * | ||||
| KR850004274A (ko) | 1983-12-13 | 1985-07-11 | 원본미기재 | 에리트로포이에틴의 제조방법 |
| NZ210501A (en) | 1983-12-13 | 1991-08-27 | Kirin Amgen Inc | Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence |
| US4703008A (en) | 1983-12-13 | 1987-10-27 | Kiren-Amgen, Inc. | DNA sequences encoding erythropoietin |
| US5856298A (en) | 1989-10-13 | 1999-01-05 | Amgen Inc. | Erythropoietin isoforms |
| US7217689B1 (en) | 1989-10-13 | 2007-05-15 | Amgen Inc. | Glycosylation analogs of erythropoietin |
| KR100221066B1 (ko) | 1989-10-13 | 1999-10-01 | 스튜어트 엘.왓트 | 에리트로포이에틴 유사체와 그를 포함하는 제약학적 조성물 |
| US5318156A (en) * | 1992-12-15 | 1994-06-07 | Honeywell Inc. | Rigid volume viscous damper |
| ZA946122B (en) | 1993-08-17 | 1995-03-20 | Amgen Inc | Erythropoietin analogs |
| US6562596B1 (en) | 1993-10-06 | 2003-05-13 | Amgen Inc. | Tissue inhibitor of metalloproteinase type three (TIMP-3) composition and methods |
| US5830851A (en) | 1993-11-19 | 1998-11-03 | Affymax Technologies N.V. | Methods of administering peptides that bind to the erythropoietin receptor |
| US5773569A (en) | 1993-11-19 | 1998-06-30 | Affymax Technologies N.V. | Compounds and peptides that bind to the erythropoietin receptor |
| US5885574A (en) | 1994-07-26 | 1999-03-23 | Amgen Inc. | Antibodies which activate an erythropoietin receptor |
| ATE306930T1 (de) | 1994-08-12 | 2005-11-15 | Immunomedics Inc | Für b-zell-lymphom und leukämiezellen spezifische immunkonjugate und humane antikörper |
| GB9504878D0 (en) | 1995-03-10 | 1995-04-26 | Weston Medical Ltd | Viscously coupled actuator |
| US5686292A (en) | 1995-06-02 | 1997-11-11 | Genentech, Inc. | Hepatocyte growth factor receptor antagonist antibodies and uses thereof |
| US5767078A (en) | 1995-06-07 | 1998-06-16 | Johnson; Dana L. | Agonist peptide dimers |
| EP1012184B1 (en) | 1997-07-14 | 2007-10-10 | Bolder Biotechnology, Inc. | Derivatives of growth hormone and related proteins |
| US6753165B1 (en) | 1999-01-14 | 2004-06-22 | Bolder Biotechnology, Inc. | Methods for making proteins containing free cysteine residues |
| PT986644E (pt) | 1997-07-23 | 2007-01-31 | Roche Diagnostics Gmbh | Preparação de eritropoietina por activação genética endógena com promotores virais |
| US6030086A (en) | 1998-03-02 | 2000-02-29 | Becton, Dickinson And Company | Flash tube reflector with arc guide |
| US6310078B1 (en) | 1998-04-20 | 2001-10-30 | Ortho-Mcneil Pharmaceutical, Inc. | Substituted amino acids as erythropoietin mimetics |
| DE19821933C1 (de) | 1998-05-15 | 1999-11-11 | Disetronic Licensing Ag | Vorrichtung zur Verabreichung eines injizierbaren Produkts |
| US20050181482A1 (en) | 2004-02-12 | 2005-08-18 | Meade Harry M. | Method for the production of an erythropoietin analog-human IgG fusion proteins in transgenic mammal milk |
| AU775422B2 (en) | 1998-06-15 | 2004-07-29 | Gtc Biotherapeutics, Inc. | Erythropoietin analog-human serum albumin fusion |
| US7798993B2 (en) * | 1998-07-29 | 2010-09-21 | Becton, Dickinson And Company | Single use syringe |
| DK1783222T3 (da) | 1998-10-23 | 2012-07-09 | Kirin Amgen Inc | Dimere trombopoietiske peptidomimetika, der binder til MPL-receptor og har trombopoietisk aktivitet |
| JP4809977B2 (ja) | 1998-10-23 | 2011-11-09 | アムジエン・インコーポレーテツド | 貧血の予防および治療用の方法および組成物 |
| SE9803662D0 (sv) | 1998-10-26 | 1998-10-26 | Pharmacia & Upjohn Ab | Autoinjector |
| US6395511B1 (en) | 1998-11-27 | 2002-05-28 | Darwin Discovery, Ltd. | Nucleic acids encoding a novel family of TGF-β binding proteins from humans |
| EP1006184A1 (en) | 1998-12-03 | 2000-06-07 | F. Hoffmann-La Roche Ag | IGF-1 receptor interacting proteins (IIPs) genes coding therefor and uses thereof |
| EP1169352A4 (en) | 1999-04-14 | 2005-05-04 | Smithkline Beecham Corp | ANTIBODY AGAINST THE ERYTHROPOIETIN RECEPTOR |
| US7297680B2 (en) | 1999-04-15 | 2007-11-20 | Crucell Holland B.V. | Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content |
| ATE308354T1 (de) | 1999-04-16 | 2005-11-15 | Becton Dickinson Co | Stiftförmiger injektor mit merkmalen zur automatischen substanzkombination |
| US6171286B1 (en) * | 1999-04-20 | 2001-01-09 | James R. Gross | Self-aligning syringe plunger |
| CZ299516B6 (cs) | 1999-07-02 | 2008-08-20 | F. Hoffmann-La Roche Ag | Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem |
| CA2388617A1 (en) | 1999-10-22 | 2001-05-03 | Millennium Pharmaceuticals, Inc. | Nucleic acid molecules derived from rat brain and programmed cell death models |
| US20050202538A1 (en) | 1999-11-12 | 2005-09-15 | Merck Patent Gmbh | Fc-erythropoietin fusion protein with improved pharmacokinetics |
| CA2391080A1 (en) | 1999-11-12 | 2001-05-25 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Erythropoietin forms with improved properties |
| KR100802403B1 (ko) | 2000-01-21 | 2008-02-13 | 바이오벡스 리미티드 | 바이러스 주 |
| AUPQ599700A0 (en) | 2000-03-03 | 2000-03-23 | Super Internet Site System Pty Ltd | On-line geographical directory |
| US6586398B1 (en) | 2000-04-07 | 2003-07-01 | Amgen, Inc. | Chemically modified novel erythropoietin stimulating protein compositions and methods |
| AU2001255516B2 (en) | 2000-04-21 | 2007-01-18 | Amgen Inc. | Methods and compositions for the prevention and treatment of anemia |
| US6756480B2 (en) | 2000-04-27 | 2004-06-29 | Amgen Inc. | Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein |
| US7078376B1 (en) | 2000-08-11 | 2006-07-18 | Baxter Healthcare S.A. | Therapeutic methods for treating subjects with a recombinant erythropoietin having high activity and reduced side effects |
| GB2366705B (en) | 2000-08-29 | 2004-07-14 | Motorola Inc | Communications system, communications unit and method of operation |
| CN1458846A (zh) | 2000-09-08 | 2003-11-26 | 格莱风治疗公司 | 促红细胞生成性合成蛋白 |
| US7271689B1 (en) | 2000-11-22 | 2007-09-18 | Fonar Corporation | Magnet structure |
| ATE505204T1 (de) | 2000-12-20 | 2011-04-15 | Hoffmann La Roche | Konjugate von erythropoietin (epo) mit polyethylenglykol (peg) |
| AR032028A1 (es) | 2001-01-05 | 2003-10-22 | Pfizer | Anticuerpos contra el receptor del factor de crecimiento similar a insulina |
| DE60232870D1 (de) | 2001-04-04 | 2009-08-20 | Genodyssee | Neue polynukleotide und polypeptide des erythropoietingens |
| ES2387546T3 (es) | 2001-05-11 | 2012-09-25 | Amgen Inc. | Péptidos y moléculas relacionadas que se unen a TALL-1 |
| ES2706902T3 (es) | 2001-06-26 | 2019-04-01 | Amgen Inc | Anticuerpos para OPGL |
| US6900292B2 (en) | 2001-08-17 | 2005-05-31 | Lee-Hwei K. Sun | Fc fusion proteins of human erythropoietin with increased biological activities |
| US7247304B2 (en) | 2001-08-23 | 2007-07-24 | Genmab A/S | Methods of treating using anti-IL-15 antibodies |
| IL160358A0 (en) | 2001-08-23 | 2004-07-25 | Genmab As | Human antibodies specific for interleukin 15 (il-15) |
| US6930086B2 (en) | 2001-09-25 | 2005-08-16 | Hoffmann-La Roche Inc. | Diglycosylated erythropoietin |
| US7214660B2 (en) | 2001-10-10 | 2007-05-08 | Neose Technologies, Inc. | Erythropoietin: remodeling and glycoconjugation of erythropoietin |
| US7521053B2 (en) | 2001-10-11 | 2009-04-21 | Amgen Inc. | Angiopoietin-2 specific binding agents |
| US7138370B2 (en) | 2001-10-11 | 2006-11-21 | Amgen Inc. | Specific binding agents of human angiopoietin-2 |
| GB0125506D0 (en) | 2001-10-24 | 2001-12-12 | Weston Medical Ltd | Needle free injection method and apparatus |
| WO2003055526A2 (en) | 2001-12-21 | 2003-07-10 | Maxygen Aps | Erythropoietin conjugates |
| US7241444B2 (en) | 2002-01-18 | 2007-07-10 | Pierre Fabre Medicament | Anti-IGF-IR antibodies and uses thereof |
| DK1461359T3 (da) | 2002-01-18 | 2007-07-09 | Pf Medicament | Hidtil ukendte anti-IGF-IR-antistoffer og anvendelser deraf |
| GB0202252D0 (en) | 2002-01-31 | 2002-03-20 | Oxford Biomedica Ltd | Anemia |
| EP1470232A1 (en) | 2002-01-31 | 2004-10-27 | Oxford Biomedica (UK) Limited | Physiologically regulated erythropoietin-expressing vector for the treatment of anaemia |
| WO2003080852A1 (en) | 2002-03-26 | 2003-10-02 | Lek Pharmaceutical And Chemical Company D.D. | Process for the preparation of a desired erythropoietin glyco-isoform profile |
| US20050283855A1 (en) | 2002-03-29 | 2005-12-22 | Koichiro Kaku | Genes encoding acetolactate synthase |
| EP1572079A4 (en) | 2002-03-29 | 2006-09-06 | Centocor Inc | MAMMAL-CDR MIMETIC BODIES, COMPOSITIONS, PROCESSES AND APPLICATION PURPOSES |
| AU2003232122A1 (en) | 2002-05-13 | 2003-11-11 | Technion Entrepreneurial Incubator Company Ltd. | Ctp-extended erythropoietin |
| GB0211294D0 (en) * | 2002-05-17 | 2002-06-26 | Owen Mumford Ltd | Improvements relating to injection devices |
| EP2316922B1 (en) | 2002-05-24 | 2013-05-22 | Merck Sharp & Dohme Corp. | Neutralizing human anti-IGFR antibody |
| US7538195B2 (en) | 2002-06-14 | 2009-05-26 | Immunogen Inc. | Anti-IGF-I receptor antibody |
| DE10226537A1 (de) | 2002-06-14 | 2004-01-08 | Peter Eichhorst | Preinjektionseinrichtung |
| US8034904B2 (en) | 2002-06-14 | 2011-10-11 | Immunogen Inc. | Anti-IGF-I receptor antibody |
| EP1575499A2 (en) | 2002-06-28 | 2005-09-21 | Centocor, Inc. | Mammalian epo mimetic ch1 deleted mimetibodies, compositions, methods and uses |
| JP2006504406A (ja) | 2002-06-28 | 2006-02-09 | セントカー・インコーポレーテツド | 哺乳動物のｃｈ１欠失ミメティボディ、組成物、方法および使用 |
| WO2004009627A1 (en) | 2002-07-19 | 2004-01-29 | Cangene Corporation | Pegylated erythropoietic compounds |
| US7097634B2 (en) * | 2002-07-31 | 2006-08-29 | Alza Corporation | Injection device providing automatic needle retraction |
| AU2003254950A1 (en) | 2002-08-26 | 2004-03-11 | Kirin Beer Kabushiki Kaisha | Peptides and drugs containing the same |
| PL377091A1 (pl) | 2002-09-06 | 2006-01-23 | Amgen, Inc. | Ludzkie monoklonalne przeciwciało przeciw-IL-1R1, o właściwościach terapeutycznych |
| AU2003255406B2 (en) | 2002-09-11 | 2009-09-10 | Fresenius Kabi Deutschland Gmbh | Hydroxyalkyl starch derivatives |
| US9486581B2 (en) | 2002-09-11 | 2016-11-08 | Becton, Dickinson And Company | Injector device with force lock-out and injection rate limiting mechanisms |
| US6919426B2 (en) | 2002-09-19 | 2005-07-19 | Amgen Inc. | Peptides and related molecules that modulate nerve growth factor activity |
| US20040071694A1 (en) | 2002-10-14 | 2004-04-15 | Devries Peter J. | Erythropoietin receptor binding antibodies |
| TWI320716B (en) | 2002-10-14 | 2010-02-21 | Abbott Lab | Erythropoietin receptor binding antibodies |
| US7396913B2 (en) | 2002-10-14 | 2008-07-08 | Abbott Laboratories | Erythropoietin receptor binding antibodies |
| WO2004034988A2 (en) | 2002-10-16 | 2004-04-29 | Amgen Inc. | Human anti-ifn-ϝ neutralizing antibodies as selective ifn-ϝ pathway inhibitors |
| US20040091961A1 (en) | 2002-11-08 | 2004-05-13 | Evans Glen A. | Enhanced variants of erythropoietin and methods of use |
| US6939319B1 (en) | 2002-11-20 | 2005-09-06 | Conrad Anstead | Process and device for single use, needle-free intradermal, subcutaneous, or intramuscular injections |
| GB2396816A (en) * | 2002-12-17 | 2004-07-07 | Pa Consulting Services | Injection device |
| EP2272864A3 (en) | 2002-12-20 | 2011-02-16 | Amgen Inc. | Binding agents which inhibit myostatin |
| WO2004057959A2 (en) * | 2002-12-20 | 2004-07-15 | Generipharm, Inc. | Intracutaneous injection |
| EP1603948A1 (en) | 2003-03-14 | 2005-12-14 | Pharmacia Corporation | Antibodies to igf-i receptor for the treatment of cancers |
| JP4473257B2 (ja) | 2003-04-02 | 2010-06-02 | エフ．ホフマン−ラ ロシュ アーゲー | インスリン様成長因子ｉ受容体に対する抗体及びその使用 |
| US7220410B2 (en) | 2003-04-18 | 2007-05-22 | Galaxy Biotech, Llc | Monoclonal antibodies to hepatocyte growth factor |
| US7638605B2 (en) | 2003-05-01 | 2009-12-29 | ImClone, LLC | Fully human antibodies directed against the human insulin-like growth factor-1 receptor |
| TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
| AU2004238870B8 (en) | 2003-05-12 | 2010-04-15 | Affymax, Inc. | Novel peptides that bind to the erythropoietin receptor |
| EP1626983B8 (en) | 2003-05-12 | 2010-12-22 | Affymax, Inc. | Novel poly (ethylene glycol) modified erythropoietin agonists and uses thereof |
| EP1625156B1 (en) | 2003-05-12 | 2012-09-19 | Affymax, Inc. | Peptides that bind to the erythropoietin receptor |
| US7074755B2 (en) | 2003-05-17 | 2006-07-11 | Centocor, Inc. | Erythropoietin conjugate compounds with extended half-lives |
| JP2005016719A (ja) * | 2003-05-30 | 2005-01-20 | Thk Co Ltd | 制振材料及びこの制振材料を組み込んだ運動案内装置 |
| BRPI0410863A (pt) | 2003-05-30 | 2006-07-04 | Centocor Inc | formação de novos conjugados de eritropoietina usando transglutaminase |
| US20050037390A1 (en) | 2003-06-04 | 2005-02-17 | Irm Llc, A Delaware Limited Liability Company | Methods and compositions for modulating erythropoietin expression |
| AR046071A1 (es) | 2003-07-10 | 2005-11-23 | Hoffmann La Roche | Anticuerpos contra el receptor i del factor de crecimiento de tipo insulinico y los usos de los mismos |
| EA013614B1 (ru) | 2003-07-15 | 2010-06-30 | Амджен Инк. | Изолированное антитело к фактору роста нервов (ngf) и способы его применения |
| RS53476B (sr) | 2003-07-18 | 2014-12-31 | Amgen Fremont Inc. | Sredstva za specifično vezivanje faktora rasta hepatocita |
| US20050019914A1 (en) | 2003-07-24 | 2005-01-27 | Aventis Pharma Deutschland Gmbh | Perfusion process for producing erythropoietin |
| GB0317511D0 (en) | 2003-07-25 | 2003-08-27 | Biovex Ltd | Viral vectors |
| JP2007512001A (ja) | 2003-08-28 | 2007-05-17 | バイオレクシス ファーマシューティカル コーポレイション | Ｅｐｏミメティックペプチドおよび融合タンパク質 |
| CN1882355A (zh) | 2003-09-09 | 2006-12-20 | 沃伦药品公司 | 保持内源性促红细胞生成素组织保护活性的长效促红细胞生成素 |
| IL157981A (en) | 2003-09-17 | 2014-01-30 | Elcam Medical Agricultural Cooperative Ass Ltd | Auto injector |
| UA89481C2 (uk) | 2003-09-30 | 2010-02-10 | Центокор, Инк. | Еритропоетинові міметичні шарнірно-серцевинні міметитіла людини, композиції, способи та застосування |
| WO2005081687A2 (en) | 2003-09-30 | 2005-09-09 | Centocor, Inc. | Human hinge core mimetibodies, compositions, methods and uses |
| WO2005047331A2 (en) | 2003-11-07 | 2005-05-26 | Immunex Corporation | Antibodies that bind interleukin-4 receptor |
| TW200526684A (en) | 2003-11-21 | 2005-08-16 | Schering Corp | Anti-IGFR1 antibody therapeutic combinations |
| US8633157B2 (en) | 2003-11-24 | 2014-01-21 | Novo Nordisk A/S | Glycopegylated erythropoietin |
| US20070254834A1 (en) | 2003-11-24 | 2007-11-01 | Defrees Shawn | Glycopegylated Erythropoietin |
| WO2005058967A2 (en) | 2003-12-16 | 2005-06-30 | Pierre Fabre Medicament | Novel anti-insulin/igf-i hybrid receptor or anti-insulin/igf-i hybrid receptor and igf-ir antibodies and uses thereof |
| EP1548031A1 (en) | 2003-12-22 | 2005-06-29 | Dubai Genetics FZ-LLC | Nature-identical erythropoietin |
| KR20060124656A (ko) | 2003-12-31 | 2006-12-05 | 메르크 파텐트 게엠베하 | 개선된 약물동태를 가지는 Ｆｃ-에리스로포이에틴 융합단백질 |
| CN1902311A (zh) | 2003-12-31 | 2007-01-24 | 森托科尔公司 | 具有n－末端游离硫羟基的新的重组蛋白 |
| US7967772B2 (en) | 2004-01-12 | 2011-06-28 | Iscience Interventional Corporation | Injector for viscous materials |
| US7423139B2 (en) | 2004-01-20 | 2008-09-09 | Insight Biopharmaceuticals Ltd. | High level expression of recombinant human erythropoietin having a modified 5′-UTR |
| US20050187158A1 (en) | 2004-01-22 | 2005-08-25 | Ranby Mats G. | Pharmaceutical composition |
| WO2005084711A1 (en) | 2004-03-02 | 2005-09-15 | Chengdu Institute Of Biological Products | A pegylated recombinant erythropoietin that has in vivo activity |
| WO2005092369A2 (en) | 2004-03-11 | 2005-10-06 | Fresenius Kabi Deutschland Gmbh | Conjugates of hydroxyethyl starch and erythropoietin |
| JP2007530045A (ja) | 2004-03-23 | 2007-11-01 | アムジエン・インコーポレーテツド | ヒトｏｘ４０ｌ（ｃｄ１３４ｌ）特異性モノクローナル抗体 |
| US20050227289A1 (en) | 2004-04-09 | 2005-10-13 | Reilly Edward B | Antibodies to erythropoietin receptor and uses thereof |
| AU2005235794A1 (en) | 2004-04-23 | 2005-11-03 | Cambridge Antibody Technology Limited | Erythropoietin protein variants |
| GB2414399B (en) | 2004-05-28 | 2008-12-31 | Cilag Ag Int | Injection device |
| GB2414404B (en) | 2004-05-28 | 2009-06-03 | Cilag Ag Int | Injection device |
| EP1781697B1 (en) | 2004-07-07 | 2009-04-22 | H.Lundbeck A/S | Novel carbamylated epo and method for its production |
| FR2873699B1 (fr) | 2004-07-29 | 2009-08-21 | Pierre Fabre Medicament Sa | Nouveaux anticorps anti igf ir rt leurs utilisations |
| US20060073563A1 (en) | 2004-09-02 | 2006-04-06 | Xencor, Inc. | Erythropoietin derivatives with altered immunogenicity |
| EP1814616A1 (en) | 2004-11-04 | 2007-08-08 | Sid Technologies Llc | Automatic injector |
| JP2008519589A (ja) | 2004-11-10 | 2008-06-12 | アプラゲン ゲーエムベーハー | 造血を促進する分子 |
| MY146381A (en) | 2004-12-22 | 2012-08-15 | Amgen Inc | Compositions and methods relating relating to anti-igf-1 receptor antibodies |
| DK1850892T4 (da) | 2005-01-24 | 2023-06-06 | Antares Pharma Inc | Forfyldt nål-assisteret sprøjtejetinjektor |
| EP1841455A1 (en) | 2005-01-24 | 2007-10-10 | Amgen Inc. | Humanized anti-amyloid antibody |
| GB2424838B (en) * | 2005-04-06 | 2011-02-23 | Cilag Ag Int | Injection device (adaptable drive) |
| US7592429B2 (en) | 2005-05-03 | 2009-09-22 | Ucb Sa | Sclerostin-binding antibody |
| DE102005025424A1 (de) | 2005-06-02 | 2006-12-07 | Tecpharma Licensing Ag | Injektionsvorrichtung mit einem Drehfederantrieb |
| PT2100614E (pt) | 2005-06-17 | 2013-12-16 | Imclone Llc | Antagonistas de receptor para tratamento de cancro ósseo metastático |
| WO2007000328A1 (en) | 2005-06-27 | 2007-01-04 | Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa | Antibodies that bind to an epitope on insulin-like growth factor 1 receptor and uses thereof |
| CA2854576A1 (en) | 2005-07-18 | 2007-01-25 | Haichun Huang | Human anti-b7rp1 neutralizing antibodies |
| FR2888850B1 (fr) | 2005-07-22 | 2013-01-11 | Pf Medicament | Nouveaux anticorps anti-igf-ir et leurs applications |
| DE102005038933A1 (de) | 2005-08-17 | 2007-02-22 | L + N Plast Vertriebs Gmbh | Autoinjektionsgerät |
| PE20071101A1 (es) | 2005-08-31 | 2007-12-21 | Amgen Inc | Polipeptidos y anticuerpos |
| GB0603683D0 (en) | 2006-02-23 | 2006-04-05 | Novartis Ag | Organic compounds |
| TWI395754B (zh) | 2006-04-24 | 2013-05-11 | Amgen Inc | 人類化之ｃ-ｋｉｔ抗體 |
| US7851438B2 (en) | 2006-05-19 | 2010-12-14 | GlycoFi, Incorporated | Erythropoietin compositions |
| FR2905273B1 (fr) | 2006-09-06 | 2009-04-03 | Becton Dickinson France Soc Pa | Dispositif d'injection automatique avec moyen de temporisation. |
| CL2007002567A1 (es) | 2006-09-08 | 2008-02-01 | Amgen Inc | Proteinas aisladas de enlace a activina a humana. |
| JP2010503430A (ja) | 2006-09-15 | 2010-02-04 | テクファーマ・ライセンシング・アクチェンゲゼルシャフト | 低損失駆動部を備える注射装置 |
| CA2667869A1 (en) | 2006-11-07 | 2008-05-15 | Merck & Co., Inc. | Antagonists of pcsk9 |
| CA2668131A1 (en) | 2006-11-07 | 2008-05-15 | Merck & Co., Inc. | Antagonists of pcsk9 |
| JP5588175B2 (ja) | 2006-11-07 | 2014-09-10 | メルク・シャープ・アンド・ドーム・コーポレーション | Ｐｃｓｋ９のアンタゴニスト |
| CA2667989A1 (en) | 2006-11-07 | 2008-11-06 | Merck & Co., Inc. | Antagonists of pcsk9 |
| KR20090088950A (ko) | 2006-12-14 | 2009-08-20 | 쉐링 코포레이션 | 가공된 항-ｔｓｌｐ 항체 |
| ES2657483T3 (es) * | 2007-03-09 | 2018-03-05 | Eli Lilly And Company | Mecanismo de retardo para un dispositivo de inyección automática |
| TW200906439A (en) | 2007-04-13 | 2009-02-16 | Novartis Ag | Molecules and methods for modulating proprotein convertase subtilisin/kexin type 9 (PCSK9) |
| WO2008155365A1 (en) | 2007-06-20 | 2008-12-24 | Irm Llc | Methods and compositions for treating allergic diseases |
| US7982016B2 (en) | 2007-09-10 | 2011-07-19 | Amgen Inc. | Antigen binding proteins capable of binding thymic stromal lymphopoietin |
| CN102232088A (zh) | 2007-10-26 | 2011-11-02 | 先灵公司 | 用于治疗脂类和胆固醇疾病的抗pcsk9及方法 |
| AR070316A1 (es) | 2008-02-07 | 2010-03-31 | Merck & Co Inc | Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9) |
| AR070315A1 (es) | 2008-02-07 | 2010-03-31 | Merck & Co Inc | Anticuerpos 1b20 antagonistas de pcsk9 |
| GB0802351D0 (en) | 2008-02-08 | 2008-03-12 | Owen Mumford Ltd | Injection devices |
| CN102099069B (zh) * | 2008-05-20 | 2013-11-27 | Shl集团有限责任公司 | 用于药物输送装置的装置 |
| KR101382346B1 (ko) * | 2008-05-23 | 2014-04-08 | 현대자동차 주식회사 | 차량용 쇽 업소버 |
| DE102008044852A1 (de) * | 2008-08-28 | 2010-03-04 | Schaeffler Kg | Dämpfungsvorrichtung, insbesondere für Spannvorrichtungen von Zugmitteltrieben an oder in Verbrennungskraftmaschinen |
| TWI516501B (zh) | 2008-09-12 | 2016-01-11 | 禮納特神經系統科學公司 | Ｐｃｓｋ９拮抗劑類 |
| WO2010049239A1 (en) | 2008-10-29 | 2010-05-06 | Shl Group Ab | Injection device |
| JP5194176B2 (ja) | 2008-12-12 | 2013-05-08 | エス・ホー・エル・グループ・アクチボラゲット | 薬剤送達装置 |
| JO3672B1 (ar) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
| JO3382B1 (ar) | 2008-12-23 | 2019-03-13 | Amgen Inc | أجسام مضادة ترتبط مع مستقبل cgrp بشري |
| ATE520432T1 (de) | 2009-02-11 | 2011-09-15 | Nils Leuzinger | Injektionsvorrichtung mit druckdämpfung für die injektion eines fluids |
| DE202009001836U1 (de) | 2009-02-13 | 2009-05-20 | Dieter Hölzle Technik-Projekte GmbH | Elektromechanische Injektionsvorrichtung |
| GB0913136D0 (en) | 2009-07-28 | 2009-09-02 | Ucb Pharma Sa | Auto-injector |
| WO2011037791A1 (en) | 2009-09-25 | 2011-03-31 | Merck Sharp & Dohme Corp. | Antagonists of pcsk9 |
| US8802827B2 (en) | 2009-10-30 | 2014-08-12 | Merck Sharp & Dohme Corp. | AX1 PCSK9 antagonists |
| IN2012DN03824A (enExample) | 2009-10-30 | 2015-08-28 | Merck Sharp & Dohme | |
| AR079336A1 (es) | 2009-12-11 | 2012-01-18 | Irm Llc | Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9) |
| WO2011096907A1 (en) * | 2010-02-08 | 2011-08-11 | Insu Teknik Makina Sanayi Ve Ticaret Anonim Sirketi | Easy to produce, single piece valve body and piston body for shock absorbers |
| DK2536455T3 (da) * | 2010-02-18 | 2014-06-23 | Sanofi Aventis Deutschland | Fingerbeskyttelse til en injektionsanordning |
| EP2364740A1 (en) | 2010-03-09 | 2011-09-14 | Sanofi-Aventis Deutschland GmbH | Arrangement for transferring a translation of a drive means to a plunger |
| EP2364739A1 (en) | 2010-03-09 | 2011-09-14 | Sanofi-Aventis Deutschland GmbH | Re-usable autoinjector |
| EP2364741A1 (en) | 2010-03-09 | 2011-09-14 | Sanofi-Aventis Deutschland GmbH | Interlock mechanism for defining an operation sequence of an auto-injector |
| CN105218674A (zh) | 2010-03-11 | 2016-01-06 | 瑞纳神经科学公司 | 呈pH依赖性抗原结合的抗体 |
| EP2399627A1 (en) | 2010-06-28 | 2011-12-28 | Sanofi-Aventis Deutschland GmbH | Auto-injector |
| EP2399631A1 (en) | 2010-06-28 | 2011-12-28 | Sanofi-Aventis Deutschland GmbH | Auto-injector with injection damper |
| EP2608825B1 (en) * | 2010-08-27 | 2014-08-13 | Novo Nordisk A/S | Medical injection device |
| EP2438939A1 (en) | 2010-10-08 | 2012-04-11 | Sanofi-Aventis Deutschland GmbH | Arrangement for coupling a plunger to either a syringe or a stopper |
| WO2012054438A1 (en) | 2010-10-22 | 2012-04-26 | Schering Corporation | Anti-pcsk9 |
| EP2468337A1 (en) | 2010-12-21 | 2012-06-27 | Sanofi-Aventis Deutschland GmbH | Back-end device for an auto-injector and auto-injector |
| EP2468341A1 (en) | 2010-12-21 | 2012-06-27 | Sanofi-Aventis Deutschland GmbH | Auto-injector |
| WO2012088313A1 (en) | 2010-12-22 | 2012-06-28 | Genentech, Inc. | Anti-pcsk9 antibodies and methods of use |
| GB2487235A (en) | 2011-01-17 | 2012-07-18 | Owen Mumford Ltd | Injection device with pneumatic damping of the drive mechanism |
| US9173999B2 (en) * | 2011-01-26 | 2015-11-03 | Kaleo, Inc. | Devices and methods for delivering medicaments from a multi-chamber container |
| HRP20180959T1 (hr) | 2011-01-28 | 2018-07-27 | Sanofi Biotechnology | Ljudska protutijela za pcsk9 za uporabu u postupcima liječenja određenih skupina subjekata |
| EP2673302A1 (en) | 2011-02-11 | 2013-12-18 | Irm Llc | Pcsk9 antagonists |
| CA2832729A1 (en) | 2011-04-21 | 2012-10-26 | Abbvie Inc. | Wearable automatic injection device for controlled administration of therapeutic agents |
| JOP20200043A1 (ar) | 2011-05-10 | 2017-06-16 | Amgen Inc | طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول |
| EP2854898B1 (en) | 2012-05-31 | 2019-07-10 | SHL Medical AG | Medicament delivery device with delayed feedback mechanism |
| EP2716316A1 (en) * | 2012-10-04 | 2014-04-09 | Sanofi-Aventis Deutschland GmbH | Medicament delivery device with damping mechanism |
| US20140114248A1 (en) * | 2012-10-24 | 2014-04-24 | Nuance Designs, LLC | Power pack for an autoinjector |
| US20160067347A1 (en) | 2012-12-20 | 2016-03-10 | Amgen Inc. | Apj receptor agonists and uses thereof |
| US8591463B1 (en) | 2013-03-08 | 2013-11-26 | Teva Pharmaceutical Industries Ltd. | Re-useable injector device for syringe |
| SG11201507524TA (en) | 2013-03-14 | 2015-10-29 | Amgen Inc | Variants of tissue inhibitor of metalloproteinase type three (timp-3), compositions and methods |
| US20140274874A1 (en) | 2013-03-14 | 2014-09-18 | Amgen Inc. | Variants of tissue inhibitor of metalloproteinase type three (timp-3), compositions and methods |
| CN105025958A (zh) * | 2013-03-14 | 2015-11-04 | 伊莱利利公司 | 适用于紧凑型自动注射装置的延迟机构 |
| EP3590568A1 (de) | 2013-03-22 | 2020-01-08 | TecPharma Licensing AG | Substanzabgabevorrichtung mit signalvorrichtung |
| MX2015014289A (es) | 2013-04-10 | 2016-01-20 | Sanofi Sa | Mecanismo para controlar la velocidad de suministro y dispositivo de inyeccion. |
| EP2988799B1 (en) | 2013-04-23 | 2019-02-27 | E3D Agricultural Cooperative Association Ltd. | Automatic injection device for administration of high viscosity medication |
| US20140350517A1 (en) * | 2013-05-23 | 2014-11-27 | Allergan, Inc. | Injection device with stress protection |
| JP2016519976A (ja) | 2013-06-03 | 2016-07-11 | ノボ・ノルデイスク・エー／エス | 医療用注射装置 |
| CN105636624B (zh) | 2013-10-16 | 2019-07-26 | 诺和诺德股份有限公司 | 带有制动机构的药物输送装置 |
| WO2015073740A2 (en) * | 2013-11-13 | 2015-05-21 | Genentech, Inc. | Assisted manual injector devices and methods |
| US20180015224A1 (en) * | 2016-07-13 | 2018-01-18 | California Institute Of Technology | Dampers and Methods for Performing Measurements in an Autoinjector |
| WO2018236619A1 (en) * | 2017-06-22 | 2018-12-27 | Amgen Inc. | Device activation impact/shock reduction |
| US11504485B1 (en) * | 2021-08-18 | 2022-11-22 | Cellular Vehicles, Inc. | Cellular therapy infusion devices, systems, and methods for use |
-
2015
- 2015-05-06 SG SG10201811702TA patent/SG10201811702TA/en unknown
- 2015-05-06 WO PCT/US2015/029485 patent/WO2015171777A1/en not_active Ceased
- 2015-05-06 BR BR112016025852-5A patent/BR112016025852B1/pt active IP Right Grant
- 2015-05-06 SG SG11201609219QA patent/SG11201609219QA/en unknown
- 2015-05-06 US US15/302,116 patent/US10722655B2/en active Active
- 2015-05-06 CA CA3193070A patent/CA3193070A1/en active Pending
- 2015-05-06 CN CN201580022028.8A patent/CN106413779B/zh active Active
- 2015-05-06 EP EP20200261.4A patent/EP3785749A1/en active Pending
- 2015-05-06 EP EP15724142.3A patent/EP3139977B1/en active Active
- 2015-05-06 AU AU2015256082A patent/AU2015256082C1/en active Active
- 2015-05-06 CA CA2945026A patent/CA2945026C/en active Active
- 2015-05-06 JP JP2016566215A patent/JP6640113B2/ja active Active
- 2015-05-06 MX MX2016014561A patent/MX388536B/es unknown
- 2015-05-06 KR KR1020167029388A patent/KR102496507B1/ko active Active
-
2016
- 2016-09-20 IL IL247935A patent/IL247935B/en active IP Right Grant
-
2019
- 2019-12-24 JP JP2019232375A patent/JP7123898B2/ja active Active
-
2020
- 2020-06-19 US US16/905,960 patent/US12029882B2/en active Active
-
2022
- 2022-05-02 JP JP2022075795A patent/JP7487257B2/ja active Active
-
2024
- 2024-06-14 US US18/744,036 patent/US20240325651A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR102496507B1 (ko) | 2023-02-03 |
| JP7487257B2 (ja) | 2024-05-20 |
| SG10201811702TA (en) | 2019-01-30 |
| IL247935B (en) | 2020-08-31 |
| AU2015256082B2 (en) | 2020-02-27 |
| CN106413779B (zh) | 2020-06-05 |
| US10722655B2 (en) | 2020-07-28 |
| SG11201609219QA (en) | 2016-12-29 |
| WO2015171777A1 (en) | 2015-11-12 |
| CN106413779A (zh) | 2017-02-15 |
| IL247935A0 (en) | 2016-11-30 |
| EP3139977B1 (en) | 2021-02-17 |
| MX388536B (es) | 2025-03-20 |
| JP7123898B2 (ja) | 2022-08-23 |
| AU2015256082C1 (en) | 2020-09-10 |
| US20200316303A1 (en) | 2020-10-08 |
| CA2945026A1 (en) | 2015-11-12 |
| MX2016014561A (es) | 2017-06-21 |
| US12029882B2 (en) | 2024-07-09 |
| JP6640113B2 (ja) | 2020-02-05 |
| JP2020072938A (ja) | 2020-05-14 |
| BR112016025852B1 (pt) | 2022-11-01 |
| US20240325651A1 (en) | 2024-10-03 |
| KR20160149198A (ko) | 2016-12-27 |
| US20170182253A1 (en) | 2017-06-29 |
| JP2022101692A (ja) | 2022-07-06 |
| AU2015256082A1 (en) | 2016-10-06 |
| EP3139977A1 (en) | 2017-03-15 |
| EP3785749A1 (en) | 2021-03-03 |
| CA2945026C (en) | 2023-10-10 |
| BR112016025852A2 (pt) | 2017-10-17 |
| JP2017518791A (ja) | 2017-07-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240325651A1 (en) | Autoinjector with shock reducing elements | |
| US11541183B2 (en) | Device activation impact/shock reduction | |
| EP3164175B1 (en) | Autoinjector with low energy plunger loading | |
| US11872374B2 (en) | Drug delivery device having a needle guard mechanism with a tunable threshold of resistance to needle guard movement | |
| US20250050026A1 (en) | Injection systems for drug delivery with internal force transmission |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20230315 |
|
| EEER | Examination request |
Effective date: 20230315 |
|
| EEER | Examination request |
Effective date: 20230315 |
|
| EEER | Examination request |
Effective date: 20230315 |
|
| EEER | Examination request |
Effective date: 20230315 |